Results 131 to 140 of about 4,877,486 (248)
Obesity, Volume 34, Issue 9, Page 1742-1758, September 2026.ABSTRACT Objective The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies. Methods The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies ...
W. Timothy Garvey +11 more
wiley +1 more source
Organ Medicine, Volume 3, Issue 3, Page 157-170, September 2026.Intestinal obstruction (IO) is an important but underexplored complication following simultaneous pancreas‐kidney transplantation (SPKT) and is associated with considerable morbidity and both clinical and economic burdens. In this single‐center cohort study, perioperative parameters, including demographic characteristics, surgical variables, and ...
Rongxin Chen +7 more
wiley +1 more source
Risk factors associated with gallstone disease in women
, 2012 Background & aims: Gallstone disease in middle-aged women has been increasing due to changing dietary and environmental factors varying from country to country.
Ullah, Shahid +6 more
core +1 more source
Phytochemicals in Food and Medicine, Volume 1, Issue 3, September 2026.Obesity and hypertension co‐exist and share molecular mechanisms in terms of dietary therapy, modulated by food bioactive constituents. ABSTRACT Obesity and hypertension are among the most pressing global public health challenges. They frequently co‐exist, with obesity‐related hypertension accounting for an estimated 75% of the hypertension burden ...
Samuel Oluwasegun Maccarthy +3 more
wiley +1 more source
Increased Risk of Gallstone Disease Following Colectomy for Ulcerative Colitis
, 2017 OBJECTIVES: Biochemical studies suggest that patients who have had a colectomy or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) are at an increased risk of developing gallstone disease, but epidemiological studies are lacking.
Brandsborg, Søren +13 more
core +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.ABSTRACT Drug Combinations offer increased therapeutic efficacy and reduced toxicity compared with single agents. Understanding a drug combination's mechanisms of action (MoA) can provide important insights into therapeutic efficacy. The MoA of many FDA‐approved drugs, however, often remains unclear.
Rui‐Sheng Wang +5 more
wiley +1 more source
United European Gastroenterology Journal, Volume 14, Issue 7, September 2026.ABSTRACT Introduction Acute pancreatitis (AP) is an inflammatory pancreatic disorder with potentially severe systemic consequences. While its immediate clinical impact is well established, the long‐term multisystem comorbidities of AP remain underexplored.
Tianyi Che +16 more
wiley +1 more source
Aging Cell, Volume 25, Issue 9, September 2026.This study provides novel insights into the metabolic correlates of epigenetic aging biomarkers and underscores the potential of metabolomics‐informed metrics of epigenetic aging as informative indicators of physiological decline and lifestyle effects.
Xunying Zhao +20 more
wiley +1 more source
Socioeconomic Status, Alcohol Use, and Mortality: Results From a Prospective Cohort Study
Alcohol, Clinical and Experimental Research, Volume 50, Issue 9, September 2026.This study examines associations of income and education, self‐reported alcohol use and alcohol biomarkers with all‐cause mortality using data from the Study of Health in Pomerania (SHIP). We observed a social gradient that was attenuated, but not fully explained by alcohol use, biomarkers, and further risk factors.
Ida Butovetsky +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8347-8358, September 2026.ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton +5 more
wiley +1 more source